Please assess the completion status of the following clinical trial:

Trial Title: A Study of Atezolizumab in Advanced Solid Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically documented advanced solid tumors that meet protocol-defined cohort specifications, have progressive disease at study entry, and have received at least one line of prior systemic therapy or for which no alternative therapy to prolong survival exists~* Representative formalin-fixed paraffin-embedded (FFPE) tumor specimens in paraffin blocks (preferred) or in freshly cut and unstained slides (exceptional cases) with an associated pathology report for central testing~* Measurable disease as defined by RECIST v1.1 or disease-specific criteria for prostate cancer and malignant pleural mesothelioma~* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1~* Negative serum pregnancy test result within 14 days prior to study drug among women of childbearing potential~* Life expectancy \> 3 months~Exclusion Criteria:~* Malignancies other than disease under study within 5 years prior to Day 1 of Cycle 1 except those with a negligible risk of metastasis or death~* Uncontrolled tumor-related pain~* Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures \>/=1 time per month~* History of asymptomatic or symptomatic central nervous system (CNS) metastasis~* Leptomeningeal disease~* Spinal cord compression not definitively treated with surgery and/or radiation, or previously diagnosed and treated but without evidence that disease has been clinically stable for \>/=2 weeks prior to Day 1 of Cycle 1~* Pregnant and lactating women~* Significant cardiovascular disease within 3 months prior to Day 1 of Cycle 1~* Severe infection within 4 weeks prior to Day 1 of Cycle 1~* Oral or IV antibiotics within 2 weeks prior to Day 1 of Cycle 1~* History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins~* Known hypersensitivity or allergy to biopharmaceuticals produced in Chinese hamster ovary cells or to any component of the atezolizumab formulation~* History of autoimmune disease except treated/stable hypothyroidism, Type 1 diabetes mellitus, and protocol-specified dermatologic conditions~* Active tuberculosis~* Signs or symptoms of infection within 2 weeks prior to Day 1 of Cycle 1~* Prior treatment with cluster of differentiation (CD) 137 agonists or immune checkpoint blockade therapies, or anti-programmed cell death-1 (PD-1) or anti-PD-L1 therapeutic antibodies~* Treatment with systemic corticosteroids or other systemic immunosuppressive medications within 2 weeks prior to Day 1 of Cycle 1, or anticipated requirement for systemic immunosuppressive medications during the trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Atezolizumab (Type: EXPERIMENTAL): The dose of atezolizumab in this study will be 1200 milligrams (mg) administered by intravenous (IV) infusion on Day 1 of each 3-week cycle until disease progression or unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).